BNC-101

N/A

Report date: 2022/10/21 17:09:16

Base Information

Drug NameBNC-101
Drug Alias NameET-101BNC-101
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanized
Mechanisms of ActionLeucine-rich repeat-containing G-protein coupled receptor 5 antagonistsWnt signalling pathway modulators
TargetsLeucine-rich repeat-containing G-protein coupled receptor 5
Therapy Area/IndicationsColorectal Neoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryN/A
CombinationsNo
Global Highest StatusPending (Phase 1 Clinical)
Highest Status in ChinaN/A
Originator CompaniesBiogen Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesCarina Biotech Pty LtdBiogen IncBionomics Ltd
Active IndicationsN/A
Inactive IndicationsColorectal Neoplasms

Other Information

ATC CodeN/A
Related LinksN/A